FDA offers Pfizer priority review for tafamidis; Clarivate to merge with Churchill Capital
→ The FDA is giving Pfizer’s tafamidis a quick look over in advance of a likely approval. The agency will give the drug a priority review for transthyretin amyloid cardiomyopathy — offering to lop months off the process. Of course, that presumes the FDA will be back in business soon.
→ Clarivate Analytics is merging with Churchill Capital. The combined company will have an enterprise value of $4.2 billion.